Hopes for new Alzheimer’s drug dashed

Source: BBC

By 

A major trial of a drug to treat mild dementia due to Alzheimer’s disease has ended in failure.

Patients on solanezumab did not show any slowing in cognitive decline compared to those treated with a placebo, or dummy drug.

The results of the trial were much anticipated after promising data was released last year.

The phase 3 trial, called EXPEDITION3, involved more than 2,000 patients with Alzheimer’s disease.

The drug targeted the build up of amyloid protein, which forms sticky plaques in the brain of patients with Alzheimer’s.

It is thought the formation of these plaques between nerve cells, known as neurons, leads to damage and eventually brain cell death.

Dementia now leading cause of death

How close are we to stopping Alzheimer’s?

There are several amyloid-clearance drugs going through trials, but solanezumab was at the most advanced stage of development.

These results were the last major hurdle before Lilly could seek to get the drug licenced, which will not now happen.

Read more

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.